HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mandatory, Voluntary Recalls Distress Supplement Firms

This article was originally published in The Tan Sheet

Executive Summary

Because a consent decree stipulated FDA could order Kabco Pharmaceuticals to recall products if the firm was found in violation, the enforcement did not emanate from the agency’s mandatory recall authority. Purity First Products, meanwhile, argues that FDA wrongly claimed the firm refused to conduct a recall.

You may also be interested in...



In Brief

FDA seeks DMAA product seizure; skin tag remover study flawed – ERSP; Plan B One-Step approved fully OTC; FDA continues evaluating laxative TEA; FDA hosts supply chain public hearing; energy drink marketing to youths challenged; more news In Brief.

FDA Suspension Authority Limits Peanut Recall, But FSMA Remains Grounded

In a series of interviews, food safety experts weigh in on why the food and nutritional products industry still has work to do with the Food Safety Modernization Act not yet implemented, as illustrated by the recent salmonella contamination of peanut ingredients from Sunland Inc.

FDA Focus On Food Safety Regulations May Delay OTC And Supplement Rules

FDA will try to eke out rules on OTC drug reviews and supplement labels in 2012 with its hands full implementing the food safety act. In the latest regulatory agenda, FDA priorities include an NPRM on foreign supplier verification and regulations to accredit third-party auditors to inspect firms across the agency’s oversight.

Related Content

Topics

UsernamePublicRestriction

Register

RS124275

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel